| Company | Date | Position | Consensus β | Price Target β | 2-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
VNDA
Vanda
|
Oct 28, 2026 | BUY |
Strong Buy
+411.2% avg upside
13 analysts
|
$11.00
190.14% Upside
|
-4.8% | Β· |
|
UTHR
United Therapeutics
|
Oct 26, 2026 | BUY |
Buy
-22.7% avg upside
27 analysts
|
$850.00
42.02% Upside
|
-1.5% | Β· |
|
ENSC
Ensysce Biosciences
|
Oct 20, 2026 | BUY |
Buy
+1919.0% avg upside
4 analysts
|
$2.00
375.11% Upside
|
-17.8% | Β· |
|
BMRN
BioMarin Pharmaceutical
|
Oct 19, 2026 | BUY |
Strong Buy
+63.6% avg upside
52 analysts
|
$86.00
47.04% Upside
|
+7.0% | Β· |
|
BRVE
Braveheart Bio, Inc.
|
Oct 19, 2026 | BUY |
Strong Buy
+95.4% avg upside
5 analysts
|
$40.00
85.92% Upside
|
-2.2% | Β· |
|
MNKD
MannKind
|
Oct 19, 2026 | BUY |
Buy
+104.0% avg upside
22 analysts
|
$8.00
128.49% Upside
|
+31.7% | Β· |
|
OMER
Omeros
|
Oct 14, 2026 | BUY |
Buy
+13.6% avg upside
14 analysts
|
$22.00
19.35% Upside
|
-24.5% | Β· |
|
CTMX
CytomX Therapeutics
|
Oct 13, 2026 | BUY |
Strong Buy
+361.2% avg upside
21 analysts
|
$12.00
412.86% Upside
|
-16.7% | Β· |
|
ALNY
Alnylam Pharma
|
Sep 30, 2026 | HOLD |
Strong Buy
+76.3% avg upside
53 analysts
|
$325.00
97.03% Upside
|
-36.6% | Β· |
|
TENX
Tenax Therapeutics
|
Sep 09, 2026 | BUY |
Strong Buy
+1239.3% avg upside
9 analysts
|
$35.00
1855.24% Upside
|
-30.5% | Β· |
|
MIST
Milestone Pharmaceuticals
|
Aug 20, 2026 | BUY |
Strong Buy
+910.2% avg upside
8 analysts
|
$3.00
310.96% Upside
|
-59.9% | Β· |
|
IRLA
IRulya Therapeutics
|
Aug 17, 2026 | BUY |
Buy
+434.4% avg upside
19 analysts
|
$70.00
112.45% Upside
|
+16.7% | Β· |
|
INSM
Insmed
|
Aug 06, 2026 | BUY |
Strong Buy
+51.3% avg upside
37 analysts
|
$235.00
108.80% Upside
|
-8.1% | Β· |
|
CNTB
Connect Biopharma Holdings
|
May 21, 2026 | BUY |
Strong Buy
+718.8% avg upside
12 analysts
|
$4.00
398.72% Upside
|
-75.5% | Β· |
|
IKT
Inhibikase Therapeutics
|
May 18, 2026 | BUY |
Strong Buy
+252.8% avg upside
9 analysts
|
$4.00
158.15% Upside
|
-14.3% | Β· |
|
PTHS
Pelthos Therapeutics
|
Apr 01, 2026 | BUY |
Strong Buy
+396.4% avg upside
8 analysts
|
$50.00
431.93% Upside
|
-67.9% | Β· |
|
GOSS
Gossamer Bio
|
Mar 20, 2026 | HOLD |
Buy
+1287.3% avg upside
17 analysts
|
β | Β· | Β· |
|
VRTX
Vertex Pharmaceuticals
|
Feb 11, 2025 | BUY |
Strong Buy
-20.5% avg upside
62 analysts
|
$480.00
14.11% Downside
|
+17.3% | Β· |
|
AMGN
Amgen
|
Feb 05, 2025 | BUY |
Buy
-29.9% avg upside
57 analysts
|
$340.00
27.04% Downside
|
+58.3% | Β· |
|
BMY
Bristol-Myers Squibb
|
Feb 04, 2025 | HOLD |
Buy
-2.2% avg upside
42 analysts
|
$55.00
11.95% Downside
|
+15.4% | Β· |
|
GILD
Gilead Sciences
|
Nov 06, 2024 | HOLD |
Strong Buy
-27.3% avg upside
66 analysts
|
$80.00
53.09% Downside
|
+92.1% | Β· |
|
REGN
Regeneron
|
Apr 17, 2024 | HOLD |
Strong Buy
-12.2% avg upside
60 analysts
|
$925.00
0.41% Downside
|
-16.2% | Β· |
|
AUPH
Aurinia Pharmaceuticals
|
Feb 23, 2024 | BUY |
Strong Buy
-4.6% avg upside
12 analysts
|
$10.00
40.00% Downside
|
+149.2% | Β· |
|
CRSP
Crispr Therapeutics AG
|
Oct 17, 2023 | HOLD |
Buy
+45.6% avg upside
41 analysts
|
β | +58.4% | Β· |
|
LENZ
LENZ Therapeutics
|
Mar 20, 2023 | HOLD |
Buy
+470.0% avg upside
17 analysts
|
$3.00
1.68% Downside
|
+224.7% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.